LIGHTPATH TECHNOLOGIES INC

For the period ended Mar 31, 2025. Filed May 20, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 20, 2025

LPTH$7.99-0.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Consolidated Statement of Changes in Stockholders’ Equity

Condensed Consolidated Statements of Changes in Stockholders' Equity

Temporary Equity · Accumulated
Series G Convertible · Class A · Additional · Other · Total
Preferred Stock · Common Stock · Paid-in · Comphrehensive · Accumulated · Stockholders
Shares · Amount · Shares · Amount · Capital · Income · Deficit · Equity
Balances at June 30, 2024	-		-		39,254,643		$392,546		$245,140,758		$509,936		$(215,843,575)		$30,199,665
Issuance of common stock for:
Employee Stock Purchase Plan	-		-		8,232		82		10,290		-		-		10,372
Exercise of Stock Options, RSUs & RSAs, net	-		-		70,309		703		(703)		-		-
Issuance of common stock for acquisition of Visimid	-		-		279,553		2,796		318,562		-		-		321,358
Stock-based compensation on stock options, RSUs & RSAs	-		-		-		-		264,475		-		-		264,475
Foreign currency translation adjustment	-		-		-		-		-		271,594		-		271,594
Net loss	-		-		-		-		-		-		(1,622,745)		(1,622,745)
Balances at September 30, 2024	-		-		39,612,737		$396,127		$245,733,382		$781,530		$(217,466,320)		$29,444,719
Issuance of common stock for:
Exercise of Stock Options, RSUs & RSAs, net	-		-		229,097		2,291		(2,291)		-		-
Shares issued as compensation	-		-		49,000		490		89,180		-		-		89,670
Stock-based compensation on stock options, RSUs & RSAs	-		-		-		-		231,581		-		-		231,581
Foreign currency translation adjustment	-		-		-		-		-		(451,035)		-		(451,035)
Net loss	-		-		-		-		-		-		(2,611,997)		(2,611,997)
Balances at December 31, 2024					39,890,834		$398,908		$246,051,852		$330,495		$(220,078,317)		$26,702,938
Issuance of preferred stock under private equity placement, net of fees		255		19,648,488						-						-
Issuance of common stock for:
Employee Stock Purchase Plan		-		-		1,137		11		4,002		-		-		4,013
Exercise of Stock Options, RSUs & RSAs, net		-		-		238,641		2,387		788		-		-		3,175
Issuance of common stock for acquisition of Visimid		-		-		102,700		1,027		391,561		-		-		392,588
Issuance of common stock for acquisition of G5		-		-		1,972,501		19,725		4,852,343		-		-		4,872,068
Issuance of common stock under private equity placement, net of fees		-		-		687,750		6,878		1,584,014		-		-		1,590,892
Issuance of warrants under private placement, net of fees		-		-		-		-		177,445		-		-		177,445
Preferred cumulative dividends plus accretion		-		14,751,134		-		-		(14,751,134)		-		-		(14,751,134)
Stock-based compensation on stock options, RSUs & RSAs		-		-		-		-		194,303		-		-		194,303
Foreign currency translation adjustment		-		-		-		-		-		120,572		-		120,572
Net loss		-		-		-		-		-		-		(3,582,460)		(3,582,460)
Balances at March 31, 2025		255		$34,399,622		42,893,563		$428,936		$238,505,174		$451,067		$(223,660,777)		$15,724,400
Balances at June 30, 2023						37,344,739		$373,447		$242,808,771		$606,536		$(207,836,229)		$35,952,525
Issuance of common stock for:
Employee Stock Purchase Plan						14,607		146		19,573		-		-		19,719
Exercise of Stock Options, RSUs & RSAs, net						14,482		145		(145)		-		-
Issuance of common stock for acquisition of Visimid						81,610		816		149,184		-		-		150,000
Stock-based compensation on stock options, RSUs & RSAs						-		-		240,075		-		-		240,075
Foreign currency translation adjustment						-		-		-		(125,208)		-		(125,208)
Net loss						-		-		-				(1,342,376)		(1,342,376)
Balances at September 30, 2023						37,455,438		$374,554		$243,217,458		$481,328		$(209,178,605)		$34,894,735
Issuance of common stock for:
Exercise of Stock Options, RSUs & RSAs, net						93,940		940		(940)		-		-
Stock-based compensation on stock options, RSUs & RSAs						-		-		258,691		-		-		258,691
Foreign currency translation adjustment						-		-		-		259,973		-		259,973
Net loss						-		-		-		-		(1,713,663)		(1,713,663)
Balances at December 31, 2023						37,549,378		$375,494		$243,475,209		$741,301		$(210,892,268)		$33,699,736
Issuance of common stock for:
Employee Stock Purchase Plan						15,840		158		19,800		-		-		19,958
Exercise of Stock Options, RSUs & RSAs, net						225,814		2,258		(2,258)		-		-
Issuance of common stock for acquisition of Visimid						267,176		2,672		333,382		-		-		336,054
Issuance of common stock under public equity placement						68,041		680		97,528		-		-		98,208
Stock-based compensation on stock options, RSUs & RSAs						-		-		264,492		-		-		264,492
Foreign currency translation adjustment						-		-		-		(112,356)		-		(112,356)
Net loss						-		-		-				(2,597,534)		(2,597,534)
Balances at March 31, 2024						38,126,249		$381,262		$244,188,153		$628,945		$(213,489,802)		$31,708,558

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.** **

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.